Suppr超能文献

吡格列酮通过减少细胞内超氧阴离子的产生来抑制人冠状动脉内皮细胞中凝集素样氧化低密度脂蛋白受体-1(LOX-1)的表达。

Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation.

作者信息

Mehta Jawahar L, Hu Bo, Chen Jiawei, Li Dayuan

机构信息

Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, 4301 W Markham St, No. 532, Little Rock, AR 72205, USA.

出版信息

Arterioscler Thromb Vasc Biol. 2003 Dec;23(12):2203-8. doi: 10.1161/01.ATV.0000094411.98127.5F. Epub 2003 Sep 4.

Abstract

OBJECTIVE

LOX-1, a novel lectin-like receptor for oxidized LDL (ox-LDL), is expressed in response to ox-LDL, angiotensin II (Ang II), tumor necrosis factor (TNF)-alpha, and other stress stimuli. It is highly expressed in atherosclerotic tissues. Peroxisome proliferator-activated receptor (PPAR)-gamma ligands, such as pioglitazone, exert antiatherosclerotic effects. This study examined the regulation of LOX-1 expression in human coronary artery endothelial cells (HCAECs) by pioglitazone.

METHODS AND RESULTS

Fourth generation HCAECs were treated with ox-LDL, Ang II, or TNF-alpha with or without pioglitazone pretreatment. All 3 stimuli upregulated LOX-1 expression (mRNA and protein). Pioglitazone, in a concentration-dependent manner, reduced LOX-1 expression (P<0.01 versus ox-LDL, Ang II, or TNF-alpha alone). Ox-LDL, Ang II, and TNF-alpha each enhanced intracellular superoxide radical generation, and pioglitazone pretreatment reduced superoxide generation (P<0.01 versus ox-LDL, Ang II, or TNF-alpha). Furthermore, all 3 stimuli upregulated the expression of the transcription factors nuclear factor-kappaB and activator protein-1 (determined by electrophoretic mobility shift assay), and pioglitazone pretreatment reduced this expression (P<0.01 versus ox-LDL, Ang II, or TNF-alpha). To determine the biological significance of pioglitazone-mediated downregulation of LOX-1, we studied monocyte adhesion to ox-LDL-treated HCAECs. Pioglitazone reduced the adhesion of monocytes to activated HCAECs in a fashion similar to that produced by antisense to LOX-1 mRNA.

CONCLUSIONS

These observations suggest that the PPAR-gamma ligand pioglitazone reduces intracellular superoxide radical generation and subsequently reduces the expression of transcription factors, expression of the LOX-1 gene, and monocyte adhesion to activated endothelium. The salutary effect of PPAR-gamma ligands in atherogenesis may involve the inhibition of LOX-1 and the adhesion of monocytes to endothelium.

摘要

目的

凝集素样氧化型低密度脂蛋白受体1(LOX-1)是一种新型的氧化型低密度脂蛋白(ox-LDL)受体,可响应ox-LDL、血管紧张素II(Ang II)、肿瘤坏死因子(TNF)-α及其他应激刺激而表达。它在动脉粥样硬化组织中高表达。过氧化物酶体增殖物激活受体(PPAR)-γ配体,如吡格列酮,具有抗动脉粥样硬化作用。本研究检测了吡格列酮对人冠状动脉内皮细胞(HCAECs)中LOX-1表达的调控作用。

方法与结果

用ox-LDL、Ang II或TNF-α处理第四代HCAECs,同时或不同时进行吡格列酮预处理。这三种刺激均上调了LOX-1的表达(mRNA和蛋白水平)。吡格列酮呈浓度依赖性地降低LOX-1表达(与单独使用ox-LDL、Ang II或TNF-α相比,P<0.01)。ox-LDL、Ang II和TNF-α均增强了细胞内超氧阴离子的产生,而吡格列酮预处理可减少超氧阴离子的产生(与单独使用ox-LDL、Ang II或TNF-α相比,P<0.01)。此外,这三种刺激均上调了转录因子核因子κB和激活蛋白-1的表达(通过电泳迁移率变动分析测定),而吡格列酮预处理可降低这种表达(与单独使用ox-LDL、Ang II或TNF-α相比,P<0.01)。为确定吡格列酮介导的LOX-1下调的生物学意义,我们研究了单核细胞对ox-LDL处理的HCAECs的黏附情况。吡格列酮以类似于LOX-1 mRNA反义寡核苷酸的方式减少了单核细胞对活化的HCAECs的黏附。

结论

这些观察结果表明,PPAR-γ配体吡格列酮可减少细胞内超氧阴离子的产生,随后降低转录因子的表达、LOX-1基因的表达以及单核细胞对活化内皮的黏附。PPAR-γ配体在动脉粥样硬化发生发展中的有益作用可能涉及对LOX-1的抑制以及单核细胞与内皮的黏附。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验